These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38450660)

  • 21. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Mycobacterium Tuberculosis Enoyl-Acyl Carrier Protein Reductase Using Computational Tools for Identification of Potential Inhibitor and their Biological Activity.
    Kuldeep J; Sharma SK; Sharma T; Singh BN; Siddiqi MI
    Mol Inform; 2021 May; 40(5):e2000211. PubMed ID: 33283460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, anti-TB activities, and molecular docking studies of 4-(1,2,3-triazoyl)arylmethanone derivatives.
    Turkmen Y; Yagiz Erdemir G; Yuksel Mayda P; Akdemir A; Gunaydin Akyildiz A; Altundas A
    J Biochem Mol Toxicol; 2022 Apr; 36(4):e22998. PubMed ID: 35187763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity.
    Dixit SR; Joshi SD; Kulkarni VH; Jalalpure SS; Kumbar VM; Mudaraddi TY; Nadagouda MN; Aminabhavi TM
    Open Med Chem J; 2017; 11():92-108. PubMed ID: 29151986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of the human fatty acid synthase enoyl-acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition.
    Sippel KH; Vyas NK; Zhang W; Sankaran B; Quiocho FA
    J Biol Chem; 2014 Nov; 289(48):33287-95. PubMed ID: 25301948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.
    Joshi SD; Dixit SR; Kulkarni VH; Lherbet C; Nadagouda MN; Aminabhavi TM
    Eur J Med Chem; 2017 Jan; 126():286-297. PubMed ID: 27889632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-
    Khetmalis YM; Chitti S; Umarani Wunnava A; Karan Kumar B; Murali Krishna Kumar M; Murugesan S; Chandra Sekhar KVG
    RSC Med Chem; 2022 Mar; 13(3):327-342. PubMed ID: 35434623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of some novel pyrazolo[1,5-a]pyrimidine derivatives as InhA inhibitors through pharmacophore-based virtual screening and molecular docking.
    Modi P; Patel S; Chhabria MT
    J Biomol Struct Dyn; 2019 Apr; 37(7):1736-1749. PubMed ID: 29663870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, and Antimycobacterial Evaluation of Novel Tetrahydroisoquinoline Hydrazide Analogs.
    Kumar BVS; Khetmalis YM; Nandikolla A; Kumar BK; Van Calster K; Murugesan S; Cappoen D; Sekhar KVGC
    Chem Biodivers; 2023 Feb; 20(2):e202200939. PubMed ID: 36597269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of natural products against enoyl-acyl-carrier-protein reductase in malaria via combined pharmacophore modeling, molecular docking and simulations studies.
    Manhas A; Ghosh A; Verma Y; Das T; Jha PC
    J Biomol Struct Dyn; 2023 Mar; 41(5):2002-2015. PubMed ID: 35043754
    [No Abstract]   [Full Text] [Related]  

  • 32. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
    Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
    Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.
    Modi P; Patel S; Chhabria M
    Mol Divers; 2023 Aug; 27(4):1547-1566. PubMed ID: 35969333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
    Lone MY; Athar M; Gupta VK; Jha PC
    J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue.
    Veyron-Churlet R; Molle V; Taylor RC; Brown AK; Besra GS; Zanella-Cléon I; Fütterer K; Kremer L
    J Biol Chem; 2009 Mar; 284(10):6414-24. PubMed ID: 19074144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of 6-[4-(4-Propoxyphenyl)piperazin-1-yl]-9H-purine Derivatives as Antimycobacterial and Antifungal Agents: In Vitro Evaluation and In Silico Study.
    Nadaf AQA; Najare MS; Garbhagudi M; Mantur S; Sunagar MG; Gaonkar S; Joshi S; Khazi IAM
    Chem Biodivers; 2020 May; 17(5):e2000053. PubMed ID: 32170847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rethinking the MtInhA tertiary and quaternary structure flexibility: a molecular dynamics view.
    Santos Chitolina L; Norberto de Souza O; Basso LA; Saraiva Macedo Timmers LF
    J Mol Model; 2022 May; 28(6):140. PubMed ID: 35534695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid.
    Ducasse-Cabanot S; Cohen-Gonsaud M; Marrakchi H; Nguyen M; Zerbib D; Bernadou J; Daffé M; Labesse G; Quémard A
    Antimicrob Agents Chemother; 2004 Jan; 48(1):242-9. PubMed ID: 14693546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA.
    Joshi SD; More UA; Koli D; Kulkarni MS; Nadagouda MN; Aminabhavi TM
    Bioorg Chem; 2015 Apr; 59():151-67. PubMed ID: 25800133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis.
    Veyron-Churlet R; Zanella-Cléon I; Cohen-Gonsaud M; Molle V; Kremer L
    J Biol Chem; 2010 Apr; 285(17):12714-25. PubMed ID: 20178986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.